MARK CONNORS
Medical Practice in Bethesda, MD

6284254, Sep 4, 2001

May 30, 1995

8/453304

Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Alan R. Davis - Wayne PA
Michael D. Lubeck - Glenmoore PA
Bernard H. Selling - Bryn Mawr PA

The United States of America as represented by the Department of Health and
Human Services - Washington DC

A61K 39155

4242111

The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and children throughout the world. RSV is a major cause of pneumonia and bronchiolitis in infants under one year of age, and is a major cause of fatal respiratory tract disease in these infants. The treatment and prevention of RSV infection has been problematic. However, the present invention addresses some of these concerns by providing attenuated RSV strains that are suitable for inclusion in immunizing compositions. Specifically, the present invention is directed toward the introduction of growth restriction mutations into incompletely attenuated host range-restricted cold-passaged respiratory syncytial virus (cpRSV) strains by further passage of the strains at increasingly reduced temperatures to produce derivative strains which are more satisfactorily attenuated. These cold-adaptation (ca) approaches were used to introduce further attenuation in the parental RSV virus cpRSV-3131, which is incompletely attenuated in seronegative children. Mutants of the parental strain were obtained by selecting for large plaque production at reduced temperatures.

2012024, Sep 27, 2012

Mar 23, 2012

13/429279

John R. Mascola - Rockville MD, US
Richard T. Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Vellinge, SE
Mario Roederer - Washington DC, US
Zhi-yong Yang - Potomac MD, US
Gary J. Nabel - Washington DC, US
Peter D. Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
Gilad Ofek - Washington DC, US
Lawrence Shapiro - Bethesda MD, US
Jiang Zhu - Ashburn VA, US
William R. Schief - Encinitas CA, US

A61K 39/395, C12N 15/63, C12N 1/21, C12N 1/19, A61P 31/18, C12N 15/74, G01N 21/64, C07K 16/10, C12N 15/13, C12N 9/96, C12N 5/10

4241421, 435188, 4353201, 43525233, 4352523, 43525235, 43525231, 4352542, 4353391, 435 5, 436501, 53038815, 5303873, 5303913, 536 2353

Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and uses of these antibodies, are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.

2011005, Mar 3, 2011

Mar 25, 2009

12/934522

Mark Connors - Bethesda MD, US
Stephen A. Migueles - Washington DC, US

The United States of America, As Represented By The Secretary, Department of - Bethesda MD

A61K 39/21, C12N 5/078, C12N 5/0783, A61P 37/04, A61P 31/18

4242081, 435325, 435375

Provided is a method of activating an immune cell of a subject with Human Immunodeficiency Virus (HIV), comprising contacting the immune cell with a phorbol ester and a calcium ionophore. Also provided is a composition comprising immune cells of a subject diagnosed with HIV, wherein the immune cells are activated by contact with a phorbol ester and a calcium ionophore. Methods of using the disclosed compositions are also disclosed.

8637036, Jan 28, 2014

Mar 23, 2012

13/429286

John R. Mascola - Rockville MD, US
Richard T. Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Vellinge, SE
Mario Roederer - Washington DC, US
Zhi-yong Yang - Potomac MD, US
Gary J. Nabel - Washington DC, US
Peter D. Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
William R. Schief - Encinitas CA, US

The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
University of Washington - Seattle WA

A61K 39/42, A61K 39/21, C12Q 1/70

4241601, 4242081, 435 5

Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.

5922326, Jul 13, 1999

Oct 21, 1994

8/327263

Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD

The United States of America, as represented by the Department of Health
& Human Services - Washington DC

A61K 39155, C12N 704, C12N 708

4242111

The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.

5882651, Mar 16, 1999

May 30, 1995

8/453294

Brian R. Murphy - Bethesda MD
Robert M. Chanock - Bethesda MD
James E. Crowe - Chevy Chase MD
Mark Connors - Chevy Chase MD
Alan R. Davis - Wayne PA
Michael D. Lubeck - Glenmoore PA
Bernard H. Selling - Bryn Mawr PA

United States of America - Washington DC
American Home Products Corporation - Parsippany NJ

A61K 39155, C12N 704, C12N 706, C12N 708

4242111

The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.

2012028, Nov 8, 2012

Sep 24, 2010

13/498125

John R. Mascola - Rockville MD, US
Richard Wyatt - San Diego CA, US
Xueling Wu - Potomac MD, US
Yuxing Li - Boyds MD, US
Carl-Magnus Hogerkorp - Malmo, SE
Mario Roederer - Bethesda MD, US
Zhi-yong Yang - Potomac MD, US
Gary Nabel - Washington DC, US
Peter Kwong - Washington DC, US
Tongqing Zhou - Boyds MD, US
Mark Connors - Bethesda MD, US
Gilad Ofek - Washington DC, US
Lawrence Shapiro - Bethesda MD, US
Jiang Zhu - Bethesda MD, US
William R. Schief - Seattle WA, US

C07K 16/10, A61K 39/42, C12N 15/13, C12N 1/21, C12N 15/74, G01N 33/569, A61P 31/18, G01N 33/577, C12N 9/96, C12N 15/63

4241421, 53038815, 5303873, 5303913, 435188, 536 2353, 4353201, 5303894, 435 5, 436501, 43525231, 4352523, 43525235

Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.